RxDoctor Payments Data

Ira Perry, MD

Cardiovascular Disease · Tarzana, CANPI 1699752956

Payments from drug & device makers

$582in general payments, 2019–2025

Across 17 payments — averaging $34.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$171
  • Novartis$93
  • Irhythm Technologies, Inc.$70
  • Abbott$65
  • Bardy Diagnostics, Inc.$62
  • E.r. Squibb & Sons, L.L.C.$52
  • plus $70 from 3 others

What the payments were for

  • Food & beverage$56497%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic2$171
Novartis3$93
Irhythm Technologies, Inc.2$70
Abbott2$65
Bardy Diagnostics, Inc.3$62
E.r. Squibb & Sons, L.L.C.2$52
Pfizer1$29
Heartflow, Inc.1$21
Boehringer Ingelheim1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$582 in reported general payments places this provider in the 25th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$598,812
Medicare patients
925
Services billed
5,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$129,231
XareltoRivaroxaban19$31,107
EntrestoSacubitril/Valsartan14$26,411
Ezetimibe69$2,582
Metoprolol Succinate96$1,737
Diltiazem 24hr Er (Cd)Diltiazem Hcl72$1,614
Atorvastatin Calcium118$1,401
Rosuvastatin Calcium72$1,346
Amlodipine Besylate111$1,342
Digoxin35$964
ClopidogrelClopidogrel Bisulfate46$955
Valsartan20$720
Losartan Potassium66$700
Hydrochlorothiazide62$427
Lisinopril62$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$129,231105 claims
NovartisEntresto$93$26,41114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →